Parnell Pharmaceuticals Holdings Ltd Announces Business Results for the Six Months Ended 30 June 2018

Author's Avatar
Apr 12, 2019
Article's Main Image

Parnell Delivers 32% Revenue Growth And A $4.0 Million Improvement In EBITDA In The First Six Months Of 2018 Compared To The Same Period In 2017, Returns To Profitability For The First Time Post-IPO And Increases 2018 Guidance To A 35% - 40% Increase In Revenue To $26 - $27 Million And An EBITDA Range Of $5.5 - $6.5 Million.